Who Exports Fulvestrant from India — 84 Suppliers Behind a $14.6M Market
India's fulvestrant export market is supplied by 84 active exporters who collectively shipped $14.6M across 487 shipments. INTAS PHARMACEUTICALS LIMITED leads with a 30.3% market share, followed by JODAS EXPOIM PRIVATE LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 75.2% of total export value, reflecting a concentrated market structure.
Top Fulvestrant Exporters from India — Ranked by Export Value
INTAS PHARMACEUTICALS LIMITED is the leading fulvestrant exporter from India, holding a 30.3% share of the $14.6M market across 487 shipments from 84 exporters. The top 5 suppliers — INTAS PHARMACEUTICALS LIMITED, JODAS EXPOIM PRIVATE LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, DR REDDYS LABORATORIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED — collectively control 75.2% of total export value, indicating a highly concentrated market. Individual shares are: INTAS PHARMACEUTICALS LIMITED (30.3%), JODAS EXPOIM PRIVATE LIMITED (12.2%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (11.4%), DR REDDYS LABORATORIES LIMITED (11.3%), ALEMBIC PHARMACEUTICALS LIMITED (9.9%).
Top Fulvestrant Exporters from India
Ranked by export value · 84 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | INTAS PHARMACEUTICALS LIMITED FULVESTRANT 250 MG/5 ML INJECTIONPHARMA DRUGS & MEDI FULVESTRANT PFS,250MFULVESTRANT INJECTION 250MG/5ML 50MG/ML | $4.4M | 11 | 30.3% |
| 2 | JODAS EXPOIM PRIVATE LIMITED FULVESTRANT INJECTION 250MG/5ML #1FULVESTRANT INJECTION 250MG/5ML PRE-FILLED SYRINGE NOSFULVESTRANT INJECTION 250MG/5ML PRE-FILLED SYRINGE | $1.8M | 3 | 12.2% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED FULVESTRANT INJECTION 250 MG/5 ML 50 MGFULVESTRANT INJ 250MG/5ML 1'S PFS IT PACFULVESTRANT INJ 250MG/5ML 2X1'S PFS GB P | $1.7M | 3 | 11.4% |
| 4 | DR REDDYS LABORATORIES LIMITED FULVESTRANT 250 MG/5 ML INJECTIONFULVESTRANT INJECTION 250MG/5ML 50MG/MLFULVESTRANT INJECTION 250 MG/5ML | $1.7M | 6 | 11.3% |
| 5 | ALEMBIC PHARMACEUTICALS LIMITED FULVESTRANT 250 MG/5 ML INJECTIONFULVESTRANT INJECTION 250MG/5ML 50MG/MLFULVESTRANT INJECTION 250 MG/5ML | $1.5M | 1 | 9.9% |
| 6 | DR REDDY S LABORATORIES LIMITED FULVESTRANT 250 MG/5 ML INJECTIONFULVESTRANT INJECTION 250MG/5ML 50MG/MLFULVESTRANT INJECTION 250 MG/5ML | $1.0M | 6 | 7.1% |
| 7 | EUGIA PHARMA SPECIALITIES LIMITED FULVESTRANT 250 MG/5 ML INJECTIONFULVESTRANT INJECTION 250MG/5ML 50MG/MLFULVESTRANT INJECTION 250 MG/5ML | $689.4K | 2 | 4.7% |
| 8 | AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED FULVESTRANT 250 MG/5 ML INJECTIONFULVESTRANT INJECTION 250MG/5ML 50MG/MLFULVESTRANT INJECTION 250 MG/5ML | $625.2K | 1 | 4.3% |
| 9 | ALEMBIC PHARMACEUTICALS LTD FULVESTRANT 250 MG/5 ML INJECTIONFULVESTRANT INJECTION 250MG/5ML 50MG/MLFULVESTRANT INJECTION 250 MG/5ML | $212.8K | 1 | 1.5% |
| 10 | INTAS PHARMACEUTICALS LTD FULVESTRANT 250 MG/5 ML INJECTIONPHARMA DRUGS & MEDI FULVESTRANT PFS,250MFULVESTRANT INJECTION 250MG/5ML 50MG/ML | $205.0K | 4 | 1.4% |
| 11 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED FULVESTRANT 250 MG/5 ML INJECTIONFULVESTRANT INJECTION 250MG/5ML 50MG/MLFULVESTRANT INJECTION 250 MG/5ML | $166.7K | 2 | 1.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Fulvestrant exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter (November | Yes (April 2007) | Yes | Not verified | Received FDA warning letter in November 2023; WHO-GMP certified in April 2007. |
| Alembic Pharmaceuticals Limited | Approved | Yes | Yes | 223 | Received multiple FDA approvals between 2024 and 2025; WHO-GMP and EU GMP certif |
| Dr. Reddy's Laboratories Limited | Approved | Yes | Yes | Not verified | FDA-approved; WHO-GMP and EU GMP certified. |
TransData Nexus reviewed the regulatory standing of 3 leading Fulvestrant exporters from India. 2 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Fulvestrant sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as "India's pharmaceutical capital," has been a pivotal center for bulk drug manufacturing since the establishment of Indian Drugs and Pharmaceuticals Limited (IDPL) in 1961. The city contributes significantly to India's bulk drug production, accounting for approximately one-third of the nation's output. This robust infrastructure supports the synthesis of active pharmaceutical ingredients (APIs) essential for medications like Fulvestrant. Notably, companies such as Natco Pharma, headquartered in Hyderabad, have a strong presence in the oncology segment, which may include drugs like Fulvestrant.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations industry. Gujarat leads India with a 33% share in drug manufacturing and a 28% share in drug exports. Vadodara, in particular, is home to Alembic Pharmaceuticals, established in 1907, which has a significant presence in the production of formulations. The region's focus on formulations positions it as a key player in the production of finished dosage forms of medications like Fulvestrant.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the export of pharmaceuticals to global markets. Companies like Sun Pharmaceutical Industries Limited, headquartered in Mumbai, have extensive export operations, contributing to India's pharmaceutical exports. This strategic location enhances the distribution of drugs like Fulvestrant to international destinations.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives. This zone attracts numerous pharmaceutical companies, contributing to the production of various drugs. While specific data on Fulvestrant production in this region is limited, the overall manufacturing capacity supports the pharmaceutical supply chain.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of suppliers, especially those in Hyderabad and Gujarat, to ensure consistent quality of Fulvestrant.
- Leverage Export Hubs: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to streamline the export process and reduce lead times.
- Monitor Regulatory Changes: Stay informed about tax incentives and regulatory policies in regions like Baddi-Nalagarh to capitalize on cost-saving opportunities.
By strategically sourcing from these diverse pharmaceutical clusters, TransData Nexus can enhance the resilience and efficiency of its Fulvestrant supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Fulvestrant exporters from India
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals acquires Aleor Dermaceuticals Ltd.
In March 2022, Alembic Pharmaceuticals Limited acquired a 100% stake in Aleor Dermaceuticals Ltd., subsequently merging it with Alembic Pharmaceuticals. IMPACT: This acquisition is expected to enhance Alembic's dermatology portfolio, potentially increasing its production capacity and export capabilities, including for products like Fulvestrant.
Impact: This acquisition is expected to enhance Alembic's dermatology portfolio, potentially increasing its production capacity and export capabilities, including for products like Fulvestrant.
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals acquires Utility Therapeutics Ltd.
In 2025, Alembic Pharmaceuticals' U.S. subsidiary acquired Utility Therapeutics Ltd. for US$12 million, adding the FDA-approved urinary tract infection drug Pivya (pivmecillinam 185 mg) to its portfolio. IMPACT: This acquisition may strengthen Alembic's presence in the U.S. market, potentially leading to increased exports of various pharmaceutical products, including Fulvestrant.
Impact: This acquisition may strengthen Alembic's presence in the U.S. market, potentially leading to increased exports of various pharmaceutical products, including Fulvestrant.
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals acquires Orit Laboratories LLC.
In 2017, Alembic Pharmaceuticals acquired Orit Laboratories LLC, a U.S.-based company, to enhance its research and development capabilities. IMPACT: This acquisition is likely to bolster Alembic's R&D efforts, potentially leading to the development and export of new formulations, including Fulvestrant.
Impact: This acquisition is likely to bolster Alembic's R&D efforts, potentially leading to the development and export of new formulations, including Fulvestrant.
Common Questions — Fulvestrant Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which fulvestrant supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, INTAS PHARMACEUTICALS LIMITED leads with 160 recorded shipments worth $4.4M. JODAS EXPOIM PRIVATE LIMITED (11 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (22 shipments) are also established high-volume exporters.
Q How many fulvestrant manufacturers are there in India?
India has 84 active fulvestrant exporters with a combined export market of $14.6M across 487 shipments to 66 countries. The top 5 suppliers hold 75.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for fulvestrant from India?
Average FOB unit price: $45.94 per unit, ranging from $0.02 to $647.00. Average shipment value: $30.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 84 verified Indian exporters of Fulvestrant ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 487 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 66 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
487 Verified Shipments
84 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists